PubRank

Stefan A Laufer

Author PubWeight™ 30.00‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 2-Acylaminopyridin-4-ylimidazoles as p38 MAP kinase inhibitors: Design, synthesis, and biological and metabolic evaluations. ChemMedChem 2009 1.69
2 Tri- and tetrasubstituted pyrazole derivates: regioisomerism switches activity from p38MAP kinase to important cancer kinases. J Med Chem 2012 1.52
3 Arylpyrrolizines as inhibitors of microsomal prostaglandin E2 synthase-1 (mPGES-1) or as dual inhibitors of mPGES-1 and 5-lipoxygenase (5-LOX). J Med Chem 2009 1.23
4 Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor. Nat Chem Biol 2011 1.05
5 Modified acidic nonsteroidal anti-inflammatory drugs as dual inhibitors of mPGES-1 and 5-LOX. J Med Chem 2012 1.03
6 Successful structure-based design of recent p38 MAP kinase inhibitors. Curr Top Med Chem 2009 0.93
7 Arachidonoyl-phosphatidylcholine oscillates during the cell cycle and counteracts proliferation by suppressing Akt membrane binding. Proc Natl Acad Sci U S A 2013 0.90
8 Discovery of novel orally active anti-inflammatory N-phenylpyrazolyl-N-glycinyl-hydrazone derivatives that inhibit TNF-α production. PLoS One 2012 0.90
9 Design and synthesis of tricyclic JAK3 inhibitors with picomolar affinities as novel molecular probes. ChemMedChem 2014 0.90
10 Identification of regioisomers in a series of N-substituted pyridin-4-yl imidazole derivatives by regiospecific synthesis, GC/MS, and 1H NMR. J Org Chem 2003 0.87
11 Catechin derivatives from Parapiptadenia rigida with in vitro wound-healing properties. J Nat Prod 2010 0.85
12 Dibenzosuberones as p38 mitogen-activated protein kinase inhibitors with low ATP competitiveness and outstanding whole blood activity. J Med Chem 2012 0.85
13 Optimization of a nonradioactive immunosorbent assay for p38alpha mitogen-activated protein kinase activity. Anal Biochem 2010 0.83
14 p38 MAPK inhibitors: a patent review (2012 - 2013). Expert Opin Ther Pat 2014 0.83
15 Entada africana fraction CH₂Cl₂/MEOH 5% inhibits inducible nitric oxide synthase and pro-inflammatory cytokines gene expression induced by lipopolysaccharide in microglia. BMC Complement Altern Med 2013 0.82
16 Are MAP kinases drug targets? Yes, but difficult ones. ChemMedChem 2007 0.82
17 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014). Expert Opin Ther Pat 2015 0.81
18 Development of first lead structures for phosphoinositide 3-kinase-C2γ inhibitors. J Med Chem 2014 0.80
19 Inhibitors of c-Jun N-terminal kinases: an update. J Med Chem 2014 0.80
20 p38α mitogen-activated protein kinase inhibitors, a patent review (2005-2011). Expert Opin Ther Pat 2011 0.79
21 Targeting the hinge glycine flip and the activation loop: novel approach to potent p38α inhibitors. J Med Chem 2012 0.79
22 Design, synthesis, and biological evaluation of novel disubstituted dibenzosuberones as highly potent and selective inhibitors of p38 mitogen activated protein kinase. J Med Chem 2012 0.79
23 Synthesis, biological testing, and binding mode prediction of 6,9-diarylpurin-8-ones as p38 MAP kinase inhibitors. J Med Chem 2007 0.78
24 Aza-analogue dibenzepinone scaffolds as p38 mitogen-activated protein kinase inhibitors: design, synthesis, and biological data of inhibitors with improved physicochemical properties. J Med Chem 2009 0.78
25 Synthesis and biological testing of N-aminoimidazole-based p38alpha MAP kinase inhibitors. ChemMedChem 2010 0.78
26 Chiral sulfoxides as metabolites of 2-thioimidazole-based p38α mitogen-activated protein kinase inhibitors: enantioselective synthesis and biological evaluation. J Med Chem 2011 0.78
27 Synthesis, p38 kinase inhibitory and anti-inflammatory activity of new substituted benzimidazole derivatives. Med Chem 2013 0.78
28 Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases. J Med Chem 2014 0.78
29 A direct ELISA assay for quantitative determination of the inhibitory potency of small molecules inhibitors for JNK3. J Pharm Biomed Anal 2011 0.77
30 Development of a p38δ mitogen activated protein kinase ELISA assay for the quantitative determination of inhibitor activity. J Pharm Biomed Anal 2012 0.77
31 N-{2-Methyl-5-[(5-oxo-10,11-dihydro-5H-dibenzo[a,d]cyclo-hepten-2-yl)amino]-phen-yl}benzamide. Acta Crystallogr Sect E Struct Rep Online 2010 0.75
32 N-[3-(5-Oxo-10,11-dihydro-5H-dibenzo[a,d]cyclo-hepten-2-ylamino)phen-yl]furan-3-carboxamide. Acta Crystallogr Sect E Struct Rep Online 2010 0.75
33 1-[4-(2-Amino-anilino)phen-yl]-2,2,2-trifluoro-ethanone. Acta Crystallogr Sect E Struct Rep Online 2010 0.75
34 Metabolically stable dibenzo[b,e]oxepin-11(6H)-ones as highly selective p38 MAP kinase inhibitors: optimizing anti-cytokine activity in human whole blood. J Med Chem 2013 0.75
35 Novel hinge-binding motifs for Janus kinase 3 inhibitors: a comprehensive structure-activity relationship study on tofacitinib bioisosteres. ChemMedChem 2014 0.75
36 Stimulating Effect of Sclareol on Suicidal Death of Human Erythrocytes. Cell Physiol Biochem 2016 0.75
37 Correction to Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases. J Med Chem 2015 0.75
38 Trisubstituted imidazoles with a rigidized hinge binding motif act as single digit nM inhibitors of clinically relevant EGFR L858R/T790M and L858R/T790M/C797S mutants: An example of target hopping. J Med Chem 2017 0.75
39 Solution-phase parallel synthesis of ruxolitinib-derived Janus kinase inhibitors via copper-catalyzed azide-alkyne cycloaddition. ACS Comb Sci 2014 0.75